Peter de Droog – Trademark Portfolio
Entity Type: 01
Peter de Droog holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 5 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include QUIRUSPON, QUIRUTAMP, and QUIRUMEDICAL.
Aletta Jacobsstraat 192
NL-2037 PE Haarlem
Showing of trademarks Trademarks
Trademark Classifications
Peter de Droog's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Peter de Droog have?
Peter de Droog has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Peter de Droog file in?
Peter de Droog files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 16 (Paper Goods), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Peter de Droog's most well-known trademarks?
Peter de Droog's registered trademark portfolio includes well-known marks such as QUIRUSPON, QUIRUTAMP, and QUIRUMEDICAL. These are among 3 currently registered trademarks in the portfolio.
What is Peter de Droog's trademark registration success rate?
Peter de Droog has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.